The GNPAT Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1975 lung adenocarcinoma cell line. This polyclonal knockout product is generated through CRISPR/Cas9-mediated disruption of the GNPAT gene, which encodes glyceronephosphate O-acyltransferase, a peroxisomal enzyme essential for ether lipid biosynthesis. The resulting polyclonal pool, comprising a heterogeneous mix of GNPAT-deficient cells, serves as a powerful tool for studying ether lipid metabolism without requiring single-cell cloning.
The parental NCI-H1975 cell line is a well-established model of EGFR-mutant non-small cell lung cancer (NSCLC), originally isolated from a 58-year-old female patient. These epithelial cells harbor activating EGFR L858R and T790M mutations along with a PIK3CA mutation, making them particularly relevant for investigating resistance mechanisms against EGFR tyrosine kinase inhibitors (TKIs). The combination of oncogenic driver mutations and a defined genetic background provides a robust platform for interrogating metabolic dependencies in lung cancer.
GNPAT catalyzes the initial and rate-limiting step of ether lipid biosynthesis: the acylation of dihydroxyacetone phosphate (DHAP) to acyl-DHAP within peroxisomes. This reaction is tightly regulated by PPAR-alpha and metabolic cues reflecting lipid availability. Downstream, the acyl-DHAP product is further processed by alkylglycerone phosphate synthase (AGPS) to generate the 1-O-alkyl glycerol backbone that serves as the precursor for plasmalogens, including ethanolamine plasmalogen (PlsEtn) and choline plasmalogen (PlsCho). GNPAT functions within a peroxisomal matrix complex alongside AGPS and other enzymes, utilizing acyl-CoA substrates. Disruption of GNPAT therefore ablates plasmalogen production, with consequences for peroxisomal lipid metabolism and cellular membrane composition.
In the context of NCI-H1975 cells, loss of GNPAT leads to a profound plasmalogen deficiency that may impair membrane biophysics and lipid-mediated signaling. Given that ether lipids are enriched in several cancer types and have been implicated in drug resistance, this knockout model enables dissection of how plasmalogen depletion affects EGFR-mutant NSCLC behavior. The interplay between oncogenic signaling and peroxisomal lipid metabolism can be systematically evaluated in these cells, shedding light on potential metabolic vulnerabilities.
Researchers can employ these polyclonal knockout cells in a variety of experimental settings, including lipidomic profiling by LC-MS to quantify ether lipid species, plasmalogen-specific assays, RT-qPCR and western blotting to confirm GNPAT ablation, and immunofluorescence visualization of peroxisomes. Metabolic labeling with [14C]-DHAP permits direct assessment of ether lipid biosynthetic activity. Functional studies such as cell viability and proliferation assays under lipid-restricted conditions further elucidate the role of plasmalogens in cancer cell survival. These applications facilitate investigations into ether lipids in lung cancer metabolism, peroxisomal disorder modeling, and lipid-dependent drug resistance mechanisms. For more information, contact Ascent Research.
